Cypre
Organoid
Platform

Human-derived tumor microenvironment organoids (TMOs) integrating immune and stromal compartments — built for MOA insights.

Tumor-stroma-immune in the Cypre Organoid Platform

Our platform enables:

Immune-and-stromal-integrated mechanism of action (MOA) analysis
Cytokine and functional immune profiling
Multi-omic readouts to support biomarker discovery
Application across bispecifics, IO agents, and tumor-specific assets

PDX-derived tumor cells

Cypre partnered with Charles River Labs to leverage their PDX tumor models listed here for Cypre 3D tumor organoids. Tumor cells have been genomically characterized for RNAseq and WES expression.

We’re selectively partnering with biopharma teams to generate next-gen MOA datasets and accelerate immunotherapy discovery.